vimarsana.com

Page 8 - Use Listing Procedure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVAX to deliver 337 million COVID-19 vaccines

Published February 4, 2021, 9:09 AM GENEVA, Switzerland (Xinhua) COVAX, the initiative led by the World Health Organization (WHO) for equitable global access to the COVID-19 vaccines, on Wednesday said it has allocated a total of 337 million doses of vaccines for poorer countries so far and will aim to deliver these in the first half of 2021. In an interim distribution forecast, the Coalition for Epidemic Preparedness Innovations (CEPI), the Vaccine Alliance Gavi and the WHO said the allocation would cover an average of 3.3 percent of the total population of over 140 countries taking part in the initial delivery round. However, COVAX also warned of various caveats, such as delays in the WHO’s Emergency Use Listing Procedure (EUL), disruptions in supply chains and logistics bottlenecks.

Bangladesh may get 12 8m doses of Oxford vaccine under COVAX by June-end

  News Desk,  bdnews24.com Published: 03 Feb 2021 10:24 PM BdST Updated: 03 Feb 2021 11:52 PM BdST A health worker prepares a dose of Oxford-AstraZeneca COVID vaccine at Dhaka’s Bangabandhu Sheikh Mujib Medical University vaccination centre on Thursday, Jan 28, 2021. Photo: Mahmud Zaman Ovi Bangladesh is expected to get 12.792 million doses of the Oxford University-AstraZeneca COVID-19 vaccine in the first half of 2021 under COVAX, the World Health Organization-led scheme says. ); } In an interim distribution forecast published on Wednesday, the facility, co-led by the GAVI vaccine alliance, said Bangladesh will get the vaccine manufactured by the Serum Institute of India. The delivery is estimated to begin as of late February, subject to WHO Emergency Use Listing Procedure, manufacturing supply capacity and completion of pre-requisites.

COVID-19 Vaccines: WHO tasks donors over funding for needy countries

The World Health Organisation (WHO) chief, Tedros Adhanom Ghebreyesus, said on Friday that there is an urgent need to address the financing gap to provide COVID-19 vaccines for everyone and everywhere. In an appeal for stepped-up funding to support poorer countries, Mr Tedros said “this week, the United Kingdom began the rollout of a vaccine developed by pharmaceutical companies, Pfizer and BioNTech, and more nations are expected to follow suit very soon.” Mr Tedros, speaking during his regular briefing from Geneva, Switzerland, said: “To have safe and effective vaccines against a virus that was completely unknown to us only a year ago is an astounding scientific achievement.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.